Calcineurin inhibitor (CNI) withdrawal showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).
It is very uncertain whether calcineurin inhibitor changes treatment response at 3 to 6 months: partial remission compared with IV cyclophosphamide (very low certainty).
Calcineurin inhibitor probably leads to lower adverse events: treatment failure at 6 months (non response, serious… compared with IV cyclophosphamide (moderate certainty).
Calcineurin inhibitor probably leads to lower adverse events: medications ceased due to adverse events compared with IV cyclophosphamide (moderate certainty).
Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).
Calcineurin inhibitor showed no clear difference in adverse events: death compared with IV cyclophosphamide (low certainty).
Calcineurin inhibitor may leads to higher treatment response at 3 to 6 months: complete or partial remission compared with IV cyclophosphamide (low certainty).
Calcineurin inhibitor may leads to higher treatment response at 3 to 6 months: complete remission compared with IV cyclophosphamide (low certainty).
Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal showed no clear difference in acute rejection: avoidance compared with standard dose CNI (low certainty).
Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal probably leads to higher acute rejection: late withdrawal compared with standard dose CNI (moderate certainty).
Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal showed no clear difference in graft loss: avoidance compared with standard dose CNI (low certainty).
Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal probably leads to lower graft loss: late withdrawal compared with standard dose CNI (moderate certainty).
Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in death compared with standard dose CNI (moderate certainty).
Calcineurin inhibitor (CNI) withdrawal + mammalian target of… probably leads to higher acute rejection compared with standard dose CNI (moderate certainty).
Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in graft loss compared with standard dose CNI (low certainty).
Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).
Calcineurin inhibitor (CNI) withdrawal + mammalian target of… probably leads to lower adverse events: CMV Infection compared with standard dose CNI (moderate certainty).
Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).